ACE-031
Not FDA approvedActivin receptor IIB decoy
Also known as: ramatercept
Early evidence, mostly unproven in humans
- Regulatory standing. Sold as a research chemical, not approved
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 4 registered studies on ClinicalTrials.gov, most advanced Phase 2
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
ACE-031, also called ramatercept, is an engineered fusion protein that combines part of the activin receptor type IIB with an antibody fragment. It is designed to act as a decoy that binds myostatin and related signaling proteins, which normally limit muscle growth. It was developed as a research drug, mainly studied for Duchenne muscular dystrophy.
What the evidence shows
It is not FDA approved. A small number of registered human trials, up to Phase 2, reported some early signals on muscle and bone measures, but development was halted over safety concerns such as nosebleeds and small blood vessel changes, so benefit in humans has not been established.
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women
Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers
Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.